943.4500 -3.85 (-0.41%)
NSE Sep 09, 2025 13:50 PM
Volume: 55,402
 

Karvy
In Q3FY18, total revenues of Alembic Pharma increased by 8% YoY to Rs8.4 bn (above our estimates Rs 7.8 bn). The Companys operating marginsincreased from 18.7% to 22.3% YoY (our estimates 22%).
Alembic Pharmaceuticals Ltd. is trading below all available SMAs
More from Alembic Pharmaceuticals Ltd.
Recommended